-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).
-
Summary
-
Supernus Pharmaceuticals, Inc. quarterly/annual Nonoperating Income (Expense) history and growth rate from 2010 to 2024.
- Supernus Pharmaceuticals, Inc. Nonoperating Income (Expense) for the quarter ending December 31, 2024 was $4.98M, a 151% increase year-over-year.
- Supernus Pharmaceuticals, Inc. Nonoperating Income (Expense) for the twelve months ending December 31, 2024 was $16.2M, a 102% increase year-over-year.
- Supernus Pharmaceuticals, Inc. annual Nonoperating Income (Expense) for 2024 was $16.2M, a 102% increase from 2023.
- Supernus Pharmaceuticals, Inc. annual Nonoperating Income (Expense) for 2023 was $8.04M, a 45% decline from 2022.
- Supernus Pharmaceuticals, Inc. annual Nonoperating Income (Expense) for 2022 was $14.6M.
Nonoperating Income (Expense), Trailing 12 Months (USD)
Nonoperating Income (Expense), Annual (USD)
Nonoperating Income (Expense), YoY Annual Growth (%)